ATE275951T1
(en)
*
|
1993-06-18 |
2004-10-15 |
Smithkline Beecham Corp |
METHOD FOR IDENTIFYING A PDE IV INHIBITOR
|
GB9312853D0
(en)
|
1993-06-22 |
1993-08-04 |
Euro Celtique Sa |
Chemical compounds
|
US6300372B1
(en)
|
1993-07-30 |
2001-10-09 |
Smithkline Beecham Corporation |
3-Cyano-3-(3,4-disubstituted) phenylcyclohexyl-1-carboxylates
|
US6013827A
(en)
*
|
1994-03-11 |
2000-01-11 |
Smithkline Beecham Corporation |
Compounds
|
GB9404706D0
(en)
*
|
1994-03-11 |
1994-04-27 |
Smithkline Beecham Corp |
Compounds
|
US5998428A
(en)
*
|
1995-05-31 |
1999-12-07 |
Smithkline Beecham Corporation |
Compounds and methods for treating PDE IV-related diseases
|
US20060019963A1
(en)
*
|
1994-06-17 |
2006-01-26 |
Smithkline Beecham Corporation |
Compounds
|
US5591776A
(en)
*
|
1994-06-24 |
1997-01-07 |
Euro-Celtique, S.A. |
Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
|
US5922751A
(en)
|
1994-06-24 |
1999-07-13 |
Euro-Celtique, S.A. |
Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
|
WO1996019994A1
(en)
*
|
1994-12-23 |
1996-07-04 |
Smithkline Beecham Corporation |
3,3-(disubstituted)cyclohexan-1-carboxylate monomers and related compounds
|
WO1996020157A1
(en)
*
|
1994-12-23 |
1996-07-04 |
Smithkline Beecham Corporation |
3,3-(disubstituted)cyclohexan-1-ol dimers and related compounds
|
WO1996020163A1
(en)
*
|
1994-12-23 |
1996-07-04 |
Smithkline Beecham Corporation |
4,4-(disubstituted)cyclohexan-1-carboxylate dimers and related compounds
|
US5863926A
(en)
*
|
1994-12-23 |
1999-01-26 |
Smithkline Beecham Corporation |
4,4-(disubstituted)cyclohexan-1-carboxylate monomers and related compounds
|
JPH10511388A
(en)
*
|
1994-12-23 |
1998-11-04 |
スミスクライン・ビーチャム・コーポレイション |
3,3- (disubstituted) cyclohexane-1-carboxylate dimer and related compounds
|
ATE231501T1
(en)
*
|
1995-05-18 |
2003-02-15 |
Altana Pharma Ag |
PHENYLDIHYDROBENZOFURANES
|
JPH11505539A
(en)
*
|
1995-05-18 |
1999-05-21 |
ビイク グルデン ロンベルク ヒェーミッシェ ファブリーク ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Cyclohexyl dihydrobenzofuran
|
US6166041A
(en)
|
1995-10-11 |
2000-12-26 |
Euro-Celtique, S.A. |
2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
|
US5891883A
(en)
*
|
1995-12-21 |
1999-04-06 |
Smithkline Beecham Corporation |
4,4-(disubstituted)cyclohexan-1-ols monomers and related compounds
|
US6075016A
(en)
|
1996-04-10 |
2000-06-13 |
Euro-Celtique S.A. |
6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
|
AP2001002304A0
(en)
*
|
1996-05-03 |
2001-12-31 |
Pfizer |
Substituted indazole derivatives and related compounds
|
JP4373497B2
(en)
|
1996-06-19 |
2009-11-25 |
ローン−プーラン・ロレ・リミテツド |
Substituted azabicyclo compounds and their use as inhibitors of TNF and cyclic AMP phosphodiesterase production
|
DE69723447T2
(en)
*
|
1996-06-25 |
2003-12-24 |
Pfizer |
SUBSTITUTED INDAZOL DERIVATIVES AND THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE (PDE) TYPE 4 AND THE TUMOR NECROSIN FACTOR (TNF)
|
WO1998022453A1
(en)
*
|
1996-11-20 |
1998-05-28 |
Byk Gulden Lomberg Chemische Fabrik Gmbh |
Substituted dihydrobenzofurans as pde inhibitors
|
AR012550A1
(en)
*
|
1997-02-12 |
2000-11-08 |
Smithkline Beecham Corp |
METHOD FOR PREPARING SUBSTITUTED 4-PHENYL-4-CIANO-CYCLOHEXANOIC ACIDS AND INTERMEDIATE COMPOUNDS
|
EP1524268B1
(en)
*
|
1997-02-12 |
2007-01-17 |
Smithkline Beecham Corporation |
Compounds and method for preparing sustituted 4-phenyl-4-cyanocyclohexanoic acids
|
SI1023279T1
(en)
*
|
1997-02-12 |
2003-12-31 |
Smithkline Beecham Corporation |
Compounds and method for preparing substituted 4-phenyl-4-cyanocyclohexanoic acids
|
UA67753C2
(en)
*
|
1997-10-10 |
2004-07-15 |
Смітклайн Бічам Корпорейшн |
Method for obtaining substituted of cyanocyclohexan acid
|
WO1999034797A1
(en)
*
|
1998-01-07 |
1999-07-15 |
Smithkline Beecham Corporation |
Method for treating multiple sclerosis
|
UY25338A1
(en)
|
1998-01-07 |
2001-08-27 |
Smithkline Beecham Corp |
METHOD FOR TREATING COPD
|
US6172118B1
(en)
*
|
1998-04-14 |
2001-01-09 |
Smithkline Beecham Corporation |
Compounds
|
US6395273B1
(en)
*
|
1998-06-10 |
2002-05-28 |
Promega Corporation |
Prevention and treatment of inflammatory bowel disease
|
US7811990B2
(en)
*
|
1998-09-25 |
2010-10-12 |
Sciaticon Ab |
Soluble cytokine receptors TNF-α blocking antibodies for treating spinal disorders mediated by nucleus pulposus
|
SE9803710L
(en)
*
|
1998-09-25 |
2000-03-26 |
A & Science Invest Ab |
Use of certain substances for the treatment of nerve root damage
|
US7906481B2
(en)
*
|
1998-09-25 |
2011-03-15 |
Sciaticon Ab |
Specific TNF-A inhibitors for treating spinal disorders mediated by nucleous pulposus
|
US7115557B2
(en)
*
|
1998-09-25 |
2006-10-03 |
Sciaticon Ab |
Use of certain drugs for treating nerve root injury
|
WO2000020391A1
(en)
|
1998-10-06 |
2000-04-13 |
Dainippon Pharmaceutical Co., Ltd. |
2,3-disubstituted pyridine derivatives, process for the preparation thereof, drug compositions containing the same and intermediates for the preparation
|
MY121142A
(en)
*
|
1999-02-23 |
2005-12-30 |
Smithkline Beecham Corp |
Controlled release formulation for treating copd
|
US6419934B1
(en)
*
|
1999-02-24 |
2002-07-16 |
Edward L. Tobinick |
TNF modulators for treating neurological disorders associated with viral infection
|
DZ3019A1
(en)
*
|
1999-03-01 |
2005-05-20 |
Smithkline Beecham Corp |
Use of a pde4 inhibitor in the preparation of a drug against copd.
|
AR035987A1
(en)
*
|
1999-03-01 |
2004-08-04 |
Smithkline Beecham Corp |
USE OF A PDE 4 INHIBITING COMPOUND FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND THE MEDICINAL PRODUCT TO TREAT ASTHMA INDUCED BY EXERCISE
|
EP1181278B1
(en)
*
|
1999-05-14 |
2004-09-29 |
Bristol-Myers Squibb Pharma Research Labs, Inc. |
Cyclic amine derivatives and their uses
|
AR024076A1
(en)
*
|
1999-05-25 |
2002-09-04 |
Smithkline Beecham Corp |
CIS- [4-CIANO-4- (3-CICLOPENTILOXI-4-METOXIFENIL) CICLOHEXAN-1-CARBOXYLATE SALTS]
|
US20040220424A1
(en)
*
|
1999-08-06 |
2004-11-04 |
Smithkline Beecham Corporation |
Process for preparing acids via alpha-chloroepoxy esters
|
ECSP003600A
(en)
*
|
1999-08-06 |
2002-03-25 |
Smithkline Beecham Corp |
METHOD FOR PREPARING CYCLHEXAN-CARBOXYL ACIDS
|
UY26268A1
(en)
*
|
1999-08-06 |
2001-01-31 |
Smithkline Beecham Corp |
PROCEDURE FOR PREPARING ACIDS THROUGH ALPHA-CHLOROEP XI- ESTERS LAW 17164 ART 127
|
US6740765B1
(en)
*
|
1999-08-06 |
2004-05-25 |
Smithkline Beecham Corporation |
Method for preparing cyclohexane carboxylic acids
|
PL200923B1
(en)
|
1999-08-21 |
2009-02-27 |
Nycomed Gmbh |
SYNERGISTIC COMBINATION OF PDE INHIBITORS AND ß₂ ADRENOCEPTOR AGONIST
|
UY26333A1
(en)
*
|
1999-09-15 |
2001-07-31 |
Smithkline Beecham Corp |
PROCEDURE AND INTERMEDIATES TO PREPARE ACIDS (4-SUBSTITUTED CYAN) - CYCLOHEXANOICS
|
AR029788A1
(en)
*
|
2000-01-12 |
2003-07-16 |
Smithkline Beecham Corp |
PROCEDURE TO REDUCE CARBOXYLIC CARBOXYLIC ACIDS ALPHA, BETA-INSATURATED, PROCEDURE TO PREPARE 4-NITRILE-4-ARYL-CYCLHEXANOIC ACIDS, PROCEDURE TO PREPARE CARBOXYLEDI-BIOPARIETHYLED INSTRUMENTED PROCEDURES
|
US20030050497A1
(en)
*
|
2002-07-11 |
2003-03-13 |
Webb Kevin Scott |
Process and intermediates for preparing a cyclohexylnitrile
|
CA2397758A1
(en)
*
|
2000-01-26 |
2001-08-02 |
Smithkline Beecham Corporation |
Monohydrate of cis-lithium-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexanecarboxylate
|
PL356447A1
(en)
*
|
2000-02-08 |
2004-06-28 |
Smithkline Beecham Corporation |
Method and compositions for treating an inflammatory disease
|
AU2001238288A1
(en)
*
|
2000-02-16 |
2001-08-27 |
University Of Nebraska Medical Center |
Method and compositions for treating fibrotic diseases
|
WO2001068600A2
(en)
|
2000-03-16 |
2001-09-20 |
Inflazyme Pharmaceuticals Limited |
Benzylated pde4 inhibitors
|
GB0011802D0
(en)
*
|
2000-05-16 |
2000-07-05 |
Smithkline Beecham |
Method for enhancing cognitive function
|
US20040005995A1
(en)
*
|
2001-07-26 |
2004-01-08 |
Edelson Jeffrey D |
Method for reducing exacerbations associated with copd
|
AU2001276497B2
(en)
|
2000-08-05 |
2005-04-07 |
Glaxo Group Limited |
17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents
|
US20040224316A1
(en)
|
2000-08-10 |
2004-11-11 |
Tully Timothy P. |
Augmented cognitive training
|
WO2003079972A2
(en)
|
2002-02-22 |
2003-10-02 |
New River Parmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
KR20030072614A
(en)
*
|
2001-01-31 |
2003-09-15 |
화이자 프로덕츠 인크. |
Thiazolyl-, Oxazolyl-, Pyrrolyl-, and Imidazolyl-Acid Amide Derivatives Useful as Inhibitors of PDE4 Isozymes
|
SK8942003A3
(en)
|
2001-01-31 |
2004-10-05 |
Pfizer Prod Inc |
Ether derivatives useful as inhibitors
|
IL156413A0
(en)
|
2001-01-31 |
2004-01-04 |
Pfizer Prod Inc |
Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes
|
US7250518B2
(en)
*
|
2001-01-31 |
2007-07-31 |
Pfizer Inc. |
Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
|
GB0103630D0
(en)
*
|
2001-02-14 |
2001-03-28 |
Glaxo Group Ltd |
Chemical compounds
|
JP4143413B2
(en)
*
|
2001-03-22 |
2008-09-03 |
グラクソ グループ リミテッド |
Formanilide derivatives as β2-adrenergic receptor agonists
|
KR100831534B1
(en)
|
2001-04-30 |
2008-05-22 |
글락소 그룹 리미티드 |
Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
|
KR20040007596A
(en)
*
|
2001-05-23 |
2004-01-24 |
다나베 세이야꾸 가부시키가이샤 |
Compositions for promoting healing of bone fracture
|
CN1537018A
(en)
*
|
2001-05-23 |
2004-10-13 |
田边制药株式会社 |
Therapeutic compositions for repairing chondropathy
|
US7361787B2
(en)
*
|
2001-09-14 |
2008-04-22 |
Glaxo Group Limited |
Phenethanolamine derivatives for treatment of respiratory diseases
|
GB0217199D0
(en)
*
|
2002-07-25 |
2002-09-04 |
Glaxo Group Ltd |
Medicament dispenser
|
GB0201677D0
(en)
*
|
2002-01-25 |
2002-03-13 |
Glaxo Group Ltd |
Medicament dispenser
|
GB0204719D0
(en)
*
|
2002-02-28 |
2002-04-17 |
Glaxo Group Ltd |
Medicinal compounds
|
JP2005523920A
(en)
*
|
2002-04-25 |
2005-08-11 |
グラクソ グループ リミテッド |
Phenetanolamine derivative
|
US20030013905A1
(en)
*
|
2002-06-10 |
2003-01-16 |
Huang Guishu Kris |
Salts of cis-4-cyano-4[3(cyclopentyloxy)-4-methoxyphenyl]cyclohexane-1-carboxylic acid
|
GB0217196D0
(en)
*
|
2002-07-25 |
2002-09-04 |
Glaxo Group Ltd |
Medicament dispenser
|
GB0217225D0
(en)
|
2002-07-25 |
2002-09-04 |
Glaxo Group Ltd |
Medicinal compounds
|
GB0217198D0
(en)
*
|
2002-07-25 |
2002-09-04 |
Glaxo Group Ltd |
Medicament dispenser
|
JP2006506373A
(en)
*
|
2002-10-22 |
2006-02-23 |
グラクソ グループ リミテッド |
Pharmaceutical arylethanolamine compounds
|
DE60320007T2
(en)
|
2002-10-28 |
2009-06-18 |
Glaxo Group Ltd., Greenford |
Phenthanolamine derivatives for the treatment of respiratory diseases
|
AU2003286024A1
(en)
*
|
2002-11-22 |
2004-06-18 |
Daniel Dube |
Use of phosphodiesterase-4 inhibitors as enhancers of cognition
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
GB0303396D0
(en)
*
|
2003-02-14 |
2003-03-19 |
Glaxo Group Ltd |
Medicinal compounds
|
EA200501548A1
(en)
|
2003-04-01 |
2006-02-24 |
Апплайд Резеч Системз Арс Холдинг Н.В. |
PHOSPHODYSTERASE INHIBITORS FOR INFERTILITY
|
WO2005002626A2
(en)
*
|
2003-04-25 |
2005-01-13 |
Gilead Sciences, Inc. |
Therapeutic phosphonate compounds
|
WO2004098578A2
(en)
*
|
2003-05-12 |
2004-11-18 |
Altana Pharma Ag |
Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517
|
WO2004098606A1
(en)
*
|
2003-05-12 |
2004-11-18 |
Altana Pharma Ag |
Composition comprising a pde4 inhibitor and shuil-1r ii
|
EP2319843B1
(en)
|
2003-05-30 |
2013-04-03 |
Ranbaxy Laboratories Limited |
Substituted pyrrole derivatives and their use as HMG-CO inhibitors
|
GB0316290D0
(en)
|
2003-07-11 |
2003-08-13 |
Glaxo Group Ltd |
Novel compounds
|
DE10331798B4
(en)
*
|
2003-07-14 |
2012-06-21 |
Giesecke & Devrient Gmbh |
Security element, valuable item, transfer material and manufacturing process
|
GB0317374D0
(en)
|
2003-07-24 |
2003-08-27 |
Glaxo Group Ltd |
Medicament dispenser
|
US20090274676A1
(en)
*
|
2003-07-31 |
2009-11-05 |
Robinson Cynthia B |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
|
US20050026883A1
(en)
*
|
2003-07-31 |
2005-02-03 |
Robinson Cynthia B. |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
|
US20050085430A1
(en)
*
|
2003-07-31 |
2005-04-21 |
Robinson Cynthia B. |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
|
GB0324654D0
(en)
*
|
2003-10-22 |
2003-11-26 |
Glaxo Group Ltd |
Medicinal compounds
|
GB0324886D0
(en)
*
|
2003-10-24 |
2003-11-26 |
Glaxo Group Ltd |
Medicinal compounds
|
GB0401334D0
(en)
|
2004-01-21 |
2004-02-25 |
Novartis Ag |
Organic compounds
|
AU2005227733A1
(en)
*
|
2004-04-02 |
2005-10-13 |
Glaxo Group Limited |
Chemical process and new crystalline form
|
GB0411056D0
(en)
|
2004-05-18 |
2004-06-23 |
Novartis Ag |
Organic compounds
|
PE20060272A1
(en)
|
2004-05-24 |
2006-05-22 |
Glaxo Group Ltd |
(2R, 3R, 4S, 5R, 2'R, 3'R, 4'S, 5'S) -2.2 '- {TRANS-1,4-CYCLOHEXANODIYLBIS- [IMINO (2 - {[2- (1-METHYL- 1H-IMIDAZOL-4-IL) ETHYL] AMINO} -9H-PURIN-6,9-DIYL)]} BIS [5- (2-ETHYL-2H-TETRAZOLE-5-IL) TETRAHYDRO-3,4-FURANODIOL] AS AN A2A AGONIST
|
TWI307630B
(en)
|
2004-07-01 |
2009-03-21 |
Glaxo Group Ltd |
Immunoglobulins
|
GB0418045D0
(en)
|
2004-08-12 |
2004-09-15 |
Glaxo Group Ltd |
Compounds
|
KR101061850B1
(en)
|
2004-09-08 |
2011-09-02 |
삼성전자주식회사 |
Thin film transistor array panel and manufacturing method thereof
|
GT200500281A
(en)
|
2004-10-22 |
2006-04-24 |
Novartis Ag |
ORGANIC COMPOUNDS.
|
GB0424284D0
(en)
|
2004-11-02 |
2004-12-01 |
Novartis Ag |
Organic compounds
|
GB0426164D0
(en)
|
2004-11-29 |
2004-12-29 |
Novartis Ag |
Organic compounds
|
EP1841780B1
(en)
*
|
2005-01-10 |
2011-07-27 |
Glaxo Group Limited |
Androstane 17-alpha-carbonate derivatives for use in the treatment of allergic and inflammatory conditions
|
US20090124588A1
(en)
*
|
2005-01-10 |
2009-05-14 |
Glaxo Group Limited |
Androstane 17-Alpha-Carbonate for Use in the Treatment of Inflammatory and Allergic Conditions
|
KR20070097106A
(en)
*
|
2005-01-11 |
2007-10-02 |
글락소 그룹 리미티드 |
Cinnamate salts of a beta-2 adrenergic agonist
|
MY145281A
(en)
|
2005-03-25 |
2012-01-13 |
Glaxo Group Ltd |
Novel compounds
|
GB0507577D0
(en)
|
2005-04-14 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
GB0514809D0
(en)
|
2005-07-19 |
2005-08-24 |
Glaxo Group Ltd |
Compounds
|
AR058104A1
(en)
|
2005-10-21 |
2008-01-23 |
Novartis Ag |
ORGANIC COMPOUNDS
|
SG166829A1
(en)
|
2005-11-08 |
2010-12-29 |
Ranbaxy Lab Ltd |
Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
|
PE20071068A1
(en)
|
2005-12-20 |
2007-12-13 |
Glaxo Group Ltd |
3- (4 - {[4- (4 - {[3- (3,3-DIMETHYL-1-PIPERIDINYL) PROPYL] OXY} PHENYL) -1-PIPERIDINYL] CARBONYL} -1-NAPHTHALENYL) PROPANOIC OR PROPENOIC ACID, SALTS OF THE SAME, AS ANTAGONISTS OF THE H1 AND H3 RECEPTORS
|
GB0526244D0
(en)
|
2005-12-22 |
2006-02-01 |
Novartis Ag |
Organic compounds
|
CN101394847B
(en)
*
|
2006-01-06 |
2017-05-24 |
塞普拉柯公司 |
Cycloalkylamines as monoamine reuptake inhibitors
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
MX2008013411A
(en)
|
2006-04-20 |
2008-11-04 |
Glaxo Group Ltd |
Novel compounds.
|
JP5373599B2
(en)
|
2006-04-21 |
2013-12-18 |
ノバルティス アーゲー |
Purine derivatives for use as adenosine A2A receptor agonists
|
SG172602A1
(en)
|
2006-05-19 |
2011-07-28 |
Helicon Therapeutics Inc |
Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
|
GB0611587D0
(en)
|
2006-06-12 |
2006-07-19 |
Glaxo Group Ltd |
Novel compounds
|
CL2007001829A1
(en)
|
2006-06-23 |
2008-01-25 |
Smithkline Beecham Corp |
N- [4-Chloro-2-hydroxy-3- (piperazine-1-sulfonyl) phenyl] -n- (2-chloro-3-fluorophenyl) urea P-toluenesulfonate; preparation process; pharmaceutical composition; pharmaceutical combination; and use in the treatment of a disease mediated by chemokine il-8, such as asthma and epoc.
|
ES2443342T3
(en)
|
2006-07-05 |
2014-02-19 |
Takeda Gmbh |
Combination of HMG-CoA reductase rosuvastatin inhibitor with a phosphodiesterase 4 inhibitor, such as roflumilast, roflumilast-N-oxide for the treatment of inflammatory lung diseases
|
CA2692428A1
(en)
*
|
2006-07-07 |
2008-01-10 |
James R. Gorman |
Methods for preventing, postponing or improving the outcome of invasive spinal procedures
|
JP2010504933A
(en)
|
2006-09-29 |
2010-02-18 |
ノバルティス アーゲー |
Pyrazolopyrimidines as PI3K lipid kinase inhibitors
|
WO2008052734A1
(en)
|
2006-10-30 |
2008-05-08 |
Novartis Ag |
Heterocyclic compounds as antiinflammatory agents
|
RU2009126633A
(en)
*
|
2006-12-13 |
2011-01-20 |
Джилид Сайэнс, Инк. (US) |
MONOPHOSPHATE COMPOUNDS, METHOD FOR PRODUCING THEREOF, AEROSOL DRUG (OPTIONS) AND METHOD FOR PREVENTING AND / OR TREATING BRONCHOSTENOSIS BY MEANS OF THE INDICATED COMPOUNDS
|
ATE493174T1
(en)
|
2007-01-10 |
2011-01-15 |
Irm Llc |
COMPOUNDS AND COMPOSITIONS AS CHANNEL-ACTIVATE PROTEASE INHIBITORS
|
AR065804A1
(en)
|
2007-03-23 |
2009-07-01 |
Smithkline Beecham Corp |
COMPOSITE OF INDOL CARBOXAMIDE, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT AND USE OF THIS COMPOUND TO PREPARE A MEDICINAL PRODUCT
|
US20090182035A1
(en)
*
|
2007-04-11 |
2009-07-16 |
Alcon Research, Ltd. |
Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
|
BRPI0810893A2
(en)
*
|
2007-04-11 |
2014-10-29 |
Alcon Res Ltd |
Use of TNF-alpha inhibitor to an antihistamine to treat allergic rhinitis and conjunctivitis, and pharmaceutical composition comprising said compounds.
|
KR20100005730A
(en)
|
2007-05-07 |
2010-01-15 |
노파르티스 아게 |
Organic compounds
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
MX354786B
(en)
|
2007-06-04 |
2018-03-21 |
Synergy Pharmaceuticals Inc |
AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER and OTHER DISORDERS.
|
EP2164825B1
(en)
*
|
2007-06-05 |
2014-04-30 |
Sanofi |
Di(hetero)arylcyclohexane derivatives, their preparation, their use and pharmaceutical compositions comprising them
|
US7943658B2
(en)
*
|
2007-07-23 |
2011-05-17 |
Bristol-Myers Squibb Company |
Indole indane amide compounds useful as CB2 agonists and method
|
TW200920369A
(en)
*
|
2007-10-26 |
2009-05-16 |
Amira Pharmaceuticals Inc |
5-lipoxygenase activating protein (flap) inhibitor
|
ES2602331T3
(en)
|
2007-12-10 |
2017-02-20 |
Novartis Ag |
Pyrazin-carboxamides of the amiloride type as ENaC blockers
|
AU2009203693B2
(en)
|
2008-01-11 |
2012-06-07 |
Novartis Ag |
Pyrimidines as kinase inhibitors
|
AU2009325091A1
(en)
|
2008-05-23 |
2010-06-17 |
Panmira Pharmaceuticals, Llc |
5-lipoxygenase-activating protein inhibitor
|
AU2009256157B2
(en)
|
2008-06-04 |
2014-12-18 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
US8163743B2
(en)
|
2008-06-05 |
2012-04-24 |
GlaxoGroupLimited |
4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases
|
WO2009147190A1
(en)
|
2008-06-05 |
2009-12-10 |
Glaxo Group Limited |
Novel compounds
|
MX2010013675A
(en)
|
2008-06-10 |
2011-02-15 |
Novartis Ag |
Pyrazine derivatives as epithelial sodium channel blockers.
|
ES2624828T3
(en)
|
2008-07-16 |
2017-07-17 |
Synergy Pharmaceuticals Inc. |
Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and others
|
EP2391366B1
(en)
|
2009-01-29 |
2012-11-28 |
Novartis AG |
Substituted benzimidazoles for the treatment of astrocytomas
|
WO2010094643A1
(en)
|
2009-02-17 |
2010-08-26 |
Glaxo Group Limited |
Quinoline derivatives and their uses for rhinitis and urticaria
|
US8524751B2
(en)
|
2009-03-09 |
2013-09-03 |
GlaxoSmithKline Intellecutual Property Development |
4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases
|
US8354539B2
(en)
|
2009-03-10 |
2013-01-15 |
Glaxo Group Limited |
Indole derivatives as IKK2 inhibitors
|
WO2010106016A1
(en)
|
2009-03-17 |
2010-09-23 |
Glaxo Group Limited |
Pyrimidine derivatives used as itk inhibitors
|
EA201171144A1
(en)
|
2009-03-19 |
2012-04-30 |
Мерк Шарп Энд Домэ Корп. |
MEDIATED RNA-INTERFERENCE INHIBITING THE EXPRESSION OF THE HOMEPHOLOGICAL GENE 1 BTB AND CNC, THE MAIN TRANSFCRIPTION FACTOR WITH LEUKIN LIGHTNING 1 (Bach1) USING SMALL INTERFACE
|
US20120029054A1
(en)
|
2009-03-19 |
2012-02-02 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA)
|
EP2408916A2
(en)
|
2009-03-19 |
2012-01-25 |
Merck Sharp&Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
JP2012520686A
(en)
|
2009-03-19 |
2012-09-10 |
メルク・シャープ・エンド・ドーム・コーポレイション |
RNA interference-mediated inhibition of signal transduction transcription factor 6 (STAT6) gene expression using small interfering nucleic acids (siNA)
|
WO2010111468A2
(en)
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
|
JP2012521764A
(en)
|
2009-03-27 |
2012-09-20 |
メルク・シャープ・エンド・ドーム・コーポレイション |
RNA interference-mediated inhibition of thymic stromal lymphocyte formation factor (TSLP) gene expression using small interfering nucleic acids (siNA)
|
US20120004282A1
(en)
|
2009-03-27 |
2012-01-05 |
Merck Sharp & Dohme Corp, |
RNA Interference Mediated Inhibition of the Intercellular Adhesion Molecule 1 (ICAM-1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
WO2010111471A2
(en)
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
JP2012521760A
(en)
|
2009-03-27 |
2012-09-20 |
メルク・シャープ・エンド・ドーム・コーポレイション |
RNA interference-mediated inhibition of apoptosis signal-regulated kinase 1 (ASK1) gene expression using small interfering nucleic acids (siNA)
|
UY32571A
(en)
|
2009-04-24 |
2010-11-30 |
Glaxo Group Ltd |
COMPOUNDS DERIVED FROM PIRAZOL AMIDA
|
WO2010122088A1
(en)
|
2009-04-24 |
2010-10-28 |
Glaxo Group Limited |
Pyrazole and triazole carboxamides as crac channel inhibitors
|
CA2759476C
(en)
|
2009-04-30 |
2018-10-09 |
Julie Nicole Hamblin |
Novel compounds
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
MX2012001838A
(en)
|
2009-08-12 |
2012-02-29 |
Novartis Ag |
Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation.
|
GEP201706639B
(en)
|
2009-08-17 |
2017-03-27 |
Intellikine Llc |
Heterocyclic compounds and uses thereof
|
KR20120089463A
(en)
|
2009-08-20 |
2012-08-10 |
노파르티스 아게 |
Heterocyclic oxime compounds
|
MX2012003693A
(en)
*
|
2009-10-01 |
2012-04-19 |
Alcon Res Ltd |
Olopatadine compositions and uses thereof.
|
EP2490687A1
(en)
|
2009-10-22 |
2012-08-29 |
Vertex Pharmaceuticals Incorporated |
Compositions for treatment of cystic fibrosis and other chronic diseases
|
WO2011067365A1
(en)
|
2009-12-03 |
2011-06-09 |
Glaxo Group Limited |
Benzpyrazole derivatives as inhibitors of p13 kinases
|
EP2507231A1
(en)
|
2009-12-03 |
2012-10-10 |
Glaxo Group Limited |
Indazole derivatives as pi 3 - kinase inhibitors
|
JP2013512878A
(en)
|
2009-12-03 |
2013-04-18 |
グラクソ グループ リミテッド |
New compounds
|
EP2512438B1
(en)
|
2009-12-16 |
2017-01-25 |
3M Innovative Properties Company |
Formulations and methods for controlling mdi particle size delivery
|
WO2011110575A1
(en)
|
2010-03-11 |
2011-09-15 |
Glaxo Group Limited |
Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
GB201007203D0
(en)
|
2010-04-29 |
2010-06-16 |
Glaxo Group Ltd |
Novel compounds
|
JP5876051B2
(en)
|
2010-09-08 |
2016-03-02 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
Indazole derivatives for use in the treatment of influenza virus infection
|
DK2614058T3
(en)
|
2010-09-08 |
2015-09-28 |
Glaxosmithkline Ip Dev Ltd |
Polymorphs, and the salts of N- [5- [4- (5 - {[(2R, 6S) -2,6-dimethyl-4-morpholinyl] methyl} -1,3-oxazol-2-yl) -1H-indazole -6-yl] -2- (methyloxy) -3-pyridinyl] methanesulfonamide.
|
WO2012034095A1
(en)
|
2010-09-09 |
2012-03-15 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
UY33597A
(en)
|
2010-09-09 |
2012-04-30 |
Irm Llc |
COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF THE TRK
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
US8372845B2
(en)
|
2010-09-17 |
2013-02-12 |
Novartis Ag |
Pyrazine derivatives as enac blockers
|
WO2012035055A1
(en)
|
2010-09-17 |
2012-03-22 |
Glaxo Group Limited |
Novel compounds
|
WO2012052459A1
(en)
|
2010-10-21 |
2012-04-26 |
Glaxo Group Limited |
Pyrazole compounds acting against allergic, inflammatory and immune disorders
|
ES2532213T3
(en)
|
2010-10-21 |
2015-03-25 |
Glaxo Group Limited |
Pyrazole compounds that act against allergic, immune and inflammatory conditions
|
GB201018124D0
(en)
|
2010-10-27 |
2010-12-08 |
Glaxo Group Ltd |
Polymorphs and salts
|
JP2014505088A
(en)
|
2011-02-10 |
2014-02-27 |
ノバルティス アーゲー |
[1,2,4] Triazolo [4,3-b] pyridazine compounds as C-MET tyrosine kinase inhibitors
|
WO2012116237A2
(en)
|
2011-02-23 |
2012-08-30 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
CN103492384B
(en)
|
2011-02-25 |
2016-05-11 |
诺华股份有限公司 |
As compound and the composition of TRK inhibitor
|
WO2012118972A2
(en)
|
2011-03-01 |
2012-09-07 |
Synegy Pharmaceuticals Inc. |
Process of preparing guanylate cyclase c agonists
|
GB201104153D0
(en)
|
2011-03-11 |
2011-04-27 |
Glaxo Group Ltd |
Novel compounds
|
WO2012123312A1
(en)
|
2011-03-11 |
2012-09-20 |
Glaxo Group Limited |
Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
|
UY34305A
(en)
|
2011-09-01 |
2013-04-30 |
Novartis Ag |
DERIVATIVES OF BICYCLIC HETEROCICLES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
|
BR112014006223A8
(en)
|
2011-09-15 |
2018-01-09 |
Novartis Ag |
6-substituted 3- (quinolin-6-ylthio) - [1,2,4-triazol [4,3-a] pyradines, their uses, pharmaceutical compositions, and combination
|
WO2013038373A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
JP5886433B2
(en)
|
2011-09-16 |
2016-03-16 |
ノバルティス アーゲー |
Heterocyclic compounds for the treatment of cystic fibrosis
|
WO2013038378A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
WO2013038390A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
N-substituted heterocyclyl carboxamides
|
WO2013038381A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine/pyrazine amide derivatives
|
EP2793893A4
(en)
|
2011-11-23 |
2015-07-08 |
Intellikine Llc |
Enhanced treatment regimens using mtor inhibitors
|
WO2013084182A1
(en)
|
2011-12-08 |
2013-06-13 |
Glenmark Pharmaceuticals S.A. |
Pharmaceutical composition that includes a pde4 enzyme inhibitor and an analgesic agent
|
US8809340B2
(en)
|
2012-03-19 |
2014-08-19 |
Novartis Ag |
Crystalline form
|
MX371119B
(en)
|
2012-04-03 |
2020-01-17 |
Novartis Ag |
Combination products with tyrosine kinase inhibitors and their use.
|
EP3718557A3
(en)
|
2013-02-25 |
2020-10-21 |
Bausch Health Ireland Limited |
Guanylate cyclase receptor agonist sp-333 for use in colonic cleansing
|
US9073921B2
(en)
|
2013-03-01 |
2015-07-07 |
Novartis Ag |
Salt forms of bicyclic heterocyclic derivatives
|
CA2905438A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
EP2968340A4
(en)
|
2013-03-15 |
2016-08-10 |
Intellikine Llc |
Combination of kinase inhibitors and uses thereof
|
AU2014235209B2
(en)
|
2013-03-15 |
2018-06-14 |
Bausch Health Ireland Limited |
Guanylate cyclase receptor agonists combined with other drugs
|
CA2913737A1
(en)
|
2013-06-05 |
2014-12-11 |
Synergy Pharmaceuticals, Inc. |
Ultra-pure agonists of guanylate cyclase c, method of making and using same
|
CA2920856A1
(en)
|
2013-08-09 |
2015-02-12 |
Ardelyx, Inc. |
Ph modulating compounds for inhibiting gastrointestinal phosphate uptake
|
US9657007B2
(en)
|
2013-09-22 |
2017-05-23 |
Calitor Sciences, Llc |
Substituted aminopyrimidine compounds and methods of use
|
JP6475707B2
(en)
|
2013-10-17 |
2019-02-27 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
PI3K inhibitors for the treatment of respiratory diseases
|
CA2923995A1
(en)
|
2013-10-17 |
2015-04-23 |
Glaxosmithkline Intellectual Property Development Limited |
Pi3k inhibitor for treatment of respiratory disease
|
TW201605450A
(en)
|
2013-12-03 |
2016-02-16 |
諾華公司 |
Combination of Mdm2 inhibitor and BRAF inhibitor and their use
|
JP6517319B2
(en)
|
2014-03-28 |
2019-05-22 |
キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーCalitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
MX2016013812A
(en)
|
2014-04-24 |
2017-03-09 |
Novartis Ag |
Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors.
|
ES2667424T3
(en)
|
2014-04-24 |
2018-05-10 |
Novartis Ag |
Pyrazine derivatives as phosphatidyl-inositol-3-kinase inhibitors
|
KR20160145780A
(en)
|
2014-04-24 |
2016-12-20 |
노파르티스 아게 |
Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
|
EA201692111A1
(en)
|
2014-05-12 |
2017-08-31 |
Глаксосмитклайн Интеллекчуал Проперти (№ 2) Лимитед |
PHARMACEUTICAL COMPOSITIONS CONTAINING DANIRYXIN FOR TREATING INFECTIOUS DISEASES
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
JP6526789B2
(en)
|
2014-07-31 |
2019-06-05 |
ノバルティス アーゲー |
Combination therapy
|
EP3347097B1
(en)
|
2015-09-11 |
2021-02-24 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
|
EP3165224A1
(en)
|
2015-11-09 |
2017-05-10 |
Albert-Ludwigs-Universität Freiburg |
Use of pde4 inhibitors for the prophylaxis and/or therapy of dyslipoproteinaemia and related disorders
|
WO2017089347A1
(en)
|
2015-11-25 |
2017-06-01 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
|
GB201602527D0
(en)
|
2016-02-12 |
2016-03-30 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
EP3497100A1
(en)
|
2016-08-08 |
2019-06-19 |
GlaxoSmithKline Intellectual Property Development Limited |
Chemical compounds
|
WO2018094392A1
(en)
|
2016-11-21 |
2018-05-24 |
Lupin Inc. |
Medicament dispenser
|
GB201706102D0
(en)
|
2017-04-18 |
2017-05-31 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
GB201712081D0
(en)
|
2017-07-27 |
2017-09-13 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
EP3710006A4
(en)
|
2017-11-19 |
2021-09-01 |
Sunshine Lake Pharma Co., Ltd. |
Substituted heteroaryl compounds and methods of use
|
AU2019209960B2
(en)
|
2018-01-20 |
2023-11-23 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
US20210085897A1
(en)
|
2018-04-06 |
2021-03-25 |
Lupin Inc. |
Medicament dispenser
|
TW201943686A
(en)
*
|
2018-04-11 |
2019-11-16 |
日商三菱瓦斯化學股份有限公司 |
Method for producing 1,4-cyclohexanedicarboxylic acid derivative, 1,4-dicyanocyclohexane, and1,4-bis(aminomethyl)cyclohexane
|
WO2020058823A1
(en)
|
2018-09-17 |
2020-03-26 |
Lupin, Inc. |
Dose indicator assembly for a medicament dispenser
|
US20200368223A1
(en)
|
2019-05-21 |
2020-11-26 |
Ardelyx, Inc. |
Methods for inhibiting phosphate transport
|
CA3139634A1
(en)
|
2019-06-10 |
2020-12-17 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
|
CA3146109A1
(en)
|
2019-08-28 |
2021-03-04 |
Novartis Ag |
Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
|
CN115916305A
(en)
|
2020-03-25 |
2023-04-04 |
陆品公司 |
Multi-carrier medicament dispenser
|
WO2021191875A1
(en)
|
2020-03-26 |
2021-09-30 |
Glaxosmithkline Intellectual Property Development Limited |
Cathepsin inhibitors for preventing or treating viral infections
|
MX2023000955A
(en)
|
2020-07-23 |
2023-04-26 |
Lupin Inc |
Dose counter assemblies for medicament dispensers.
|